GlassScriptPhysician profile
Nicholas N Jonas
NPI 1003132234
$5,869.39
in general payments reported to CMS, 2019-2025
33 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $52.84 · 2021: $252 · 2022: $839 · 2023: $1,173 · 2024: $1,364 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.89 | 2021-2025 | |
| Ucb, INC. | $818.70 | 2019-2025 | Zilbrysq, Briviact, Fintepla |
| Sk Life Science, INC. | $557.51 | 2023-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $456.44 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lilly USA, LLC | $266.20 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Pfizer INC. | $262.54 | 2023-2025 | |
| Argenx US, INC. | $211.83 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $207.22 | 2024-2025 | Vyepti |
| Celgene Corporation | $175.96 | 2022-2024 | Zeposia |
| Neurelis, INC. | $125.24 | 2023-2025 | Valtoco |
| Csl Behring | $124.26 | 2025 | Hizentra |
| Amneal Pharmaceuticals LLC | $111.53 | 2022-2025 | Rytary, Crexont |
| Biogen, INC. | $101.34 | 2019-2025 | Leqembi |
| Acorda Therapeutics, INC | $97.77 | 2019-2023 | Ampyra, Inbrija |
| Alnylam Pharmaceuticals INC. | $95.49 | 2024 | Amvuttra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $89.22 | 2021-2022 | |
| Emd Serono, INC. | $86.41 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $63.75 | 2019 | |
| Livanova USA, INC. | $51.86 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $45.83 | 2024 | |
| Boston Scientific Corporation | $44.77 | 2023 | Vercise |
| Allergan, INC. | $40.92 | 2021-2022 | |
| Amgen INC. | $38.92 | 2020-2023 | Aimovig |
| Grifols USA, LLC | $33.50 | 2024-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $27.95 | 2022 | |
| Eisai INC. | $25.04 | 2024 | |
| Tanabe Pharma America, INC. | $23.77 | 2023 | |
| Acadia Pharmaceuticals INC | $23.48 | 2024 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $22.56 | 2021 | |
| Scilex Pharmaceuticals INC. | $19.67 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.63 | 2024 | Ultomiris |
| Avinger INC. | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Jonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.